The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma
Asano, N.; Yamakazi, T.; Seto, M.; Matsumine, A.; Yoshikawa, H.; Uchida, A.
Journal of Bone and Joint Surgery. British Volume 86(4): 607-612
2004
ISSN/ISBN: 0301-620X PMID: 15174563 Document Number: 568138
We investigated the rates of expression of bone morphogenetic protein-2 (BMP-2) in 29 adult patients with high-grade malignant fibrous histiocytoma of soft tissue, using the BMP-2-specific monoclonal antibody, AbH3b2/17, and found that they ranged from 1.9% to 78.9%. The survival at five years of the groups expressing high (> or = 30%) and low (< 30%) levels of BMP-2 was 85.7% and 36.3%, respectively. Multivariable analysis showed that only BMP-2 had prognostic significance for continuous disease-free survival and for overall survival (p < 0.05). Our findings indicate that over-expression of BMP-2 in malignant fibrous histiocytoma of soft tissue is the most reliable prognostic indicator of the parameters assessed.